It has been confirmed by preclinical studies that DHMEQ inhibited activation of NF-κB and its nuclear translocation, resulting in decreased tumor growth in vivo as well as reduced proliferation in GBM cells in vitro. The gene discussed is NFKB1; the disease is glioblastoma.